NCT02990858View on ClinicalTrials.gov

An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 3, 2016

Primary Completion Date

June 30, 2022

Study Completion Date

August 31, 2022

Conditions
HivHuman Immunodeficiency Virus
Interventions
DRUG

PRO 140 SC injections

Sponsors

Lead Sponsor

CytoDyn, Inc.
All Listed Sponsors
lead

CytoDyn, Inc.

INDUSTRY

NCT02990858 - An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study | Biotech Hunter | Biotech Hunter